Kristen Riemenschneider

May 9, 2024 | lexology.com | Andrew Dockham |Beth George |Adam Golden |Vinita Kailasanath |Kristen Riemenschneider |Madeline Cimino | +1 more

Following legislation forcing ByteDance’s divestment in TikTok, anti-China sentiment on Capitol Hill has refocused on restricting the federal government from contracting companies that contract with biotech firms linked to foreign adversaries. Legislation being considered on both sides of Capitol Hill takes an aggressive stance.

Feb 12, 2024 | lexology.com | Harriet Hanks |Kristen Riemenschneider |James Smith |Jake Reynolds |Elizabeth K. Bieber |Christopher Stothers | +4 more

Antimicrobial resistance (AMR) is a growing global threat: the WHO recognises it as one of the top public health and development threats, and bacterial AMR was associated with almost 5 million global deaths in a single year in one landmark study.1 AMR’s contributing factors include a lack of new antimicrobial products, limited access to antibiotics in low- and middle-income countries, and discharge of antimicrobial waste into the environment.

Feb 12, 2024 | lifescienceleader.com | Kristen Riemenschneider |Harriet Hanks |James Smith

By Kristen Riemenschneider, Harriet Hanks, and James Smith, Freshfields Antimicrobial resistance (AMR) is a growing global threat: the WHO recognises it as one of the top public health and development threats, and bacterial AMR was associated with almost 5 million global deaths in a single year in one landmark study.1 AMR’s contributing factors include a lack of new antimicrobial products, limited access to antibiotics in low- and middle-income countries, and discharge of antimicrobial waste...

Jan 22, 2024 | lexology.com | Adam Golden |Vinita Kailasanath |Kristen Riemenschneider |Dylan O'Connor |Shannon O'Hara

The 42nd Annual J.P. Morgan Healthcare Conference brought together thousands of professionals in the biopharma, biotech and MedTech spaces to discuss the latest industry developments and forge new partnerships. Coming off an extremely active Q4 2023, the excitement over what may be in store in 2024 was palpable. However, lingering doubt continued to hover over the minds of many, with concerns about the financing environment, drug pricing reform, and looming gaps in product pipelines.

Apr 12, 2023 | lexology.com | Kristen Riemenschneider |Joshua Samuel

In our January blog post on this topic, The Drug Pricing Landscape in 2023: Renewed Pressure for Pricing Reform, we speculated that in 2023 we could see changes in the regulation of drug pricing in the U.S. It’s only the beginning of April and there have already been some notable developments—albeit in multiple directions. First, we saw some movement towards greater control over drug prices.